AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02394054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
Study NCT02956109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finerenone (BAY94-8862): 1 0mg tablet
Description: 10 mg finerenone immediate-release tablet; single dose in the fasting condition
Study NCT02956109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets
Description: 5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
Study NCT02956109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet
Description: 1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
Study NCT03848975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation training for ECV
Description: Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.
Study NCT03848975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation training for VE
Description: Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
Study NCT04213807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAA868 Cohort 1
Description: Subcutaneous injection: low dose
Study NCT04213807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAA868 Cohort 2
Description: Subcutaneous injection: high dose
Study NCT04213807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAA868 Cohort 3
Description: Subcutaneous injection: Dose to be determined.
Study NCT04213807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection: Placebo
Study NCT03263611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intradiscal injection
Study NCT03263611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG0103
Description: single intradiscal injection
Study NCT00955162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine (Subutex)
Description: Sublingual tablet
Study NCT00955162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Suboxone)
Description: Sublingual tablet
Study NCT03926026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: NCX 4251 Ophthalmic Suspension, 0.1%
Study NCT03926026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NCX 4251 Ophthalmic Suspension, 0%
Study NCT01807676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Double Lumen Tube
Study NCT03163121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine
Description: Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
Study NCT01411137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066
Description: Subjects were converted from their current treatment to IPX066 over a 6-week period.~Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules
Study NCT00569634 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venous blood gas analysis
Description: When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always \< 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
Study NCT01558908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of ERC
Description: Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
Study NCT04017611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00038
Description: Noninvasive regional oximeter
Study NCT04580004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med Optimization Arm
Description: An evidence-based medication recommendation website that is provided to the patients.
Study NCT02829398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CerebroSpinal fluid and plasma samples
Description: CerebroSpinal fluid and plasma samples for biological markers
Study NCT02829398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CerebroSpinal fluid and plasma samples
Description: CerebroSpinal fluid and plasma samples for biological markers
Study NCT01128595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/GW642444M
Study NCT03163121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
Study NCT03163121 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride
Study NCT01128595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444M
Study NCT01128595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Study NCT01128595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01841671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
Study NCT01841671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
Study NCT01841671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV
Description: As indicated
Study NCT01841671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mOPV type 2
Description: Administered at 28 weeks of age to all study participants
Study NCT01841671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV type 2
Description: Administered at 28 weeks of age to all study participants
Study NCT01841671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
Study NCT01841671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
Study NCT03163121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosquito-bite CHMI
Description: Bites of 5 infected mosquitoes of NF54 strain
Study NCT03163121 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Mosquito-bite CHMI
Description: Bites of 5 infected mosquitoes of NF54 strain
Study NCT03848208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet
Study NCT02706795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA
Description: Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
Study NCT00439309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam/Thrombin
Description: Gelfoam/Thrombin
Study NCT00439309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VascuSeal
Description: VascuSeal
Study NCT02227290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftin Cream
Study NCT02227290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study NCT02270190 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Tibial Nerve Stimulation (PTNS)
Study NCT04820634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training
Description: The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills \& concepts of job interviews. Sessions are approximately 90 minutes long.
Study NCT04820634 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wonderworks
Description: The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
Study NCT02241330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biofortified wheat
Description: Wheat was grown by foliar Zn application and is therefore biofortified
Study NCT02241330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortification
Description: Wheat flour is fortified before testmeal preparation
Study NCT02241330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: wheat flour is used as control comparator.
Study NCT03826173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPPA
Description: The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
Study NCT03826173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA
Description: The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
Study NCT02562508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 doses of HPV 16/18 bivalent vaccine
Description: Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
Study NCT02562508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2 doses of HPV 16/18 bivalent vaccine
Description: Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
Study NCT00820482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur®, Ferring
Description: 75 UI/day of Hp-hMG (Menopur®)
Study NCT01064999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: CRT:50mg/m2,IV,weekly\*5 cycle CT: 130mg/m2,IV,d1,q 21 day
Study NCT00820482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH (Gonal®,
Description: 75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
Study NCT01175356 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo radiotherapy
Study NCT01175356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous in vitro-treated peripheral blood stem cell transplantation
Study NCT01175356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01175356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01175356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01175356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01175356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study NCT01175356 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo radiotherapy
Study NCT01175356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous in vitro-treated peripheral blood stem cell transplantation
Study NCT01175356 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo radiotherapy
Study NCT01175356 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iobenguane I-131
Description: Given IV
Study NCT01175356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO
Study NCT01175356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01175356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01175356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01175356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01175356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02382276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene hydrochloride
Study NCT01175356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT01175356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02983695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL-TC150
Description: The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
Study NCT01649752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter
Study NCT00011362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Early
Description: Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
Study NCT00011362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Early
Description: Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
Study NCT00011362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Late
Description: Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was >=2.4 on treatment day 14, or an additional two weeks of saline
Study NCT00011362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Late
Description: Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was >=2.4 on treatment day 14, or an additional two weeks of saline
Study NCT01778049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Empagliflozin active
Study NCT01778049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 Placebo
Description: Empagliflozin placebo
Study NCT01778049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356
Description: Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Study NCT01778049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356
Description: Empagliflozin / Linagliptin 10/5 mg Dose FDC active
Study NCT01778049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356 Placebo
Description: Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
Study NCT01778049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356 Placebo
Description: Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Study NCT01778049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356 Placebo
Description: Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
Study NCT01649752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.
Study NCT03493373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.
Study NCT03493373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
Study NCT02178592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
Study NCT02178592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV 600 mg
Description: EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
Study NCT00511433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles.
Study NCT00511433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRSP-EE
Description: Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
Study NCT00496197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eraxis (anidulafungin)
Description: Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
Study NCT00496197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diflucan (fluconazole)
Description: Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
Study NCT00496197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend (voriconazole)
Description: Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.